Valuation: VYNE Therapeutics

Market Cap 16.98M 14.91M 13.87M 12.72M 23.91M 1.63B 24.28M 165M 64.33M 804M 63.73M 62.36M 2.78B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 16.98M 14.91M 13.87M 12.72M 23.91M 1.63B 24.28M 165M 64.33M 804M 63.73M 62.36M 2.78B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.30%
1 week-33.11%
Current month-21.78%
1 month-21.76%
3 months-21.10%
6 months-12.32%
Current year-12.26%
1 week 0.47
Extreme 0.47
0.94
1 month 0.47
Extreme 0.47
0.94
Current year 0.47
Extreme 0.47
0.94
1 year 0.28
Extreme 0.2805
1.6
3 years 0.28
Extreme 0.2805
6.79
5 years 0.28
Extreme 0.2805
52.38
10 years 0.28
Extreme 0.2805
291.6
Manager TitleAgeSince
Chief Executive Officer 60 01/03/2020
Director of Finance/CFO 40 -
Chief Tech/Sci/R&D Officer 53 01/03/2020
Director TitleAgeSince
Director/Board Member 60 01/03/2020
Director/Board Member 72 01/03/2020
Director/Board Member 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
6/30/26 A Tax

General Counsel

-3,464 0.0104%
6/30/26 A Tax

Chief Financial Officer

-3,464 0.0104%
6/30/26 A Tax

Chief Technology Officer

-2,370 0.0071%

Financials

2026 *2027 *
Net sales - -
Net income -50M -43.92M -40.84M -37.48M -70.41M -4.82B -71.5M -485M -189M -2.37B -188M -184M -8.18B -75M -65.87M -61.26M -56.21M -106M -7.22B -107M -727M -284M -3.55B -282M -275M -12.28B
Net Debt - -
Logo VYNE Therapeutics
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.
Employees
10
Sector
-
Date Price Change Volume
24/07/26 $0.5090 -44.88% 2,953,153
23/07/26 $0.9234 +2.87% 987,990
22/07/26 $0.8976 +0.55% 1,210,602
21/07/26 $0.8927 +10.51% 5,410,108
20/07/26 $0.8078 +6.15% 2,243,492
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5090
Average target price
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VYNE Stock